I studie II opretholdt 88% af de patienter, der havde klinisk betydningsfuld forbedring ved måned 12, respons ved måned 18, og 85% opretholdt respons ved måned 24.
In Study II, among patients with clinically meaningful improvement at month 12, 88% retained the response at month 18, and 85% retained the response at month 24.